Literature DB >> 2418126

Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks.

R M Hendry, A L Talis, E Godfrey, L J Anderson, B F Fernie, K McIntosh.   

Abstract

Respiratory syncytial virus (RSV) is considered to be of a single serotype. Antigenic variants are detectable both by neutralization and monoclonal antibodies and have been divided into two broad categories, groups 1 and 2. Group 2 isolates have been considered to be uncommon. We used indirect immunofluorescence with strain-specific monoclonal antibodies to study RSV isolates from hospitalized infants in the greater Boston area. Of 223 RSV isolates recovered over a five-month period in 1983-1984, 125 (56%) were group 1, 92 (41%) were group 2, and 6 (3%) were of an intermediate character. Among 181 community-acquired RSV isolates, both temporal and geographic clustering was observed: group 1 isolates were common from January through March and predominated in central Boston; group 2 isolates were found principally in February and were acquired in outlying, particularly northern, areas. Strain-specific differences were not found with respect to sex, age, or clinical findings. An analysis of 82 RSV isolates from the 1981-1982 season showed 75 (91%) group 1 isolates and 7 (9%) group 2 isolates. We conclude that at least two antigenically distinct groups of RSV isolates may circulate concurrently in the community and that the prevalence of group 2 isolates appears greater than previously suspected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418126     DOI: 10.1093/infdis/153.2.291

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Antigenic characterization of respiratory syncytial virus group A and B isolates in Rio de Janeiro, Brazil.

Authors:  M M Siqueira; J P Nascimento; L J Anderson
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Three antigenic variant groups in human respiratory syncytial virus subgroup B isolated in Japan.

Authors:  K Nagai; H Tsutsumi; H Yamazaki; S Pattamadilok; S Chiba
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Authors:  Sangeeta Kumari; Roberta Lynne Crim; Ashwin Kulkarni; Susette A Audet; Thembi Mdluli; Haruhiko Murata; Judy A Beeler
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

Review 5.  Respiratory syncytial virus genetic and antigenic diversity.

Authors:  W M Sullender
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

Review 7.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Comparison of two new tests for rapid diagnosis of respiratory syncytial virus infections by enzyme-linked immunosorbent assay and immunofluorescence techniques.

Authors:  F Freymuth; M Quibriac; J Petitjean; M L Amiel; P Pothier; A Denis; J F Duhamel
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

9.  RNA fingerprinting of respiratory syncytial virus using ribonuclease protection. Application to molecular epidemiology.

Authors:  G A Storch; C S Park; D E Dohner
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

10.  Analysis of respiratory syncytial virus genetic variability with amplified cDNAs.

Authors:  W M Sullender; L Sun; L J Anderson
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.